Tower Research Capital LLC TRC Boosts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Tower Research Capital LLC TRC grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 97.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,925 shares of the company’s stock after buying an additional 950 shares during the period. Tower Research Capital LLC TRC’s holdings in Prestige Consumer Healthcare were worth $150,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares during the last quarter. Avior Wealth Management LLC raised its position in shares of Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock valued at $668,000 after buying an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Prestige Consumer Healthcare by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after buying an additional 33,844 shares during the period. Norges Bank acquired a new stake in Prestige Consumer Healthcare during the fourth quarter worth approximately $40,009,000. Finally, Barclays PLC grew its stake in Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after acquiring an additional 71,730 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Down 2.4 %

NYSE:PBH opened at $80.99 on Wednesday. The business’s 50-day moving average is $83.15 and its two-hundred day moving average is $81.11. The firm has a market capitalization of $4.01 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 12 month low of $62.35 and a 12 month high of $90.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insider Activity

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PBH. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday, April 29th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group increased their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Royal Bank of Canada upped their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research note on Friday, March 21st. Finally, Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.